Compare LE & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LE | TLSI |
|---|---|---|
| Founded | 1963 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.9M | 250.0M |
| IPO Year | 1994 | 2020 |
| Metric | LE | TLSI |
|---|---|---|
| Price | $9.57 | $3.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $19.00 | $10.40 |
| AVG Volume (30 Days) | 151.8K | ★ 206.3K |
| Earning Date | 12-08-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 10.96 | N/A |
| Revenue | ★ $1,162,769,000.00 | $45,151,000.00 |
| Revenue This Year | N/A | $17.65 |
| Revenue Next Year | $4.10 | $40.27 |
| P/E Ratio | $0.89 | ★ N/A |
| Revenue Growth | 0.72 | ★ 53.41 |
| 52 Week Low | $9.56 | $2.20 |
| 52 Week High | $20.04 | $7.95 |
| Indicator | LE | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 30.66 |
| Support Level | N/A | $3.05 |
| Resistance Level | $10.78 | $3.68 |
| Average True Range (ATR) | 0.40 | 0.21 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 5.58 | 7.07 |
Lands' End Inc is a United States-based digital retailer of solution-based apparel, swimwear, outerwear, accessories, footwear, home products, and uniforms. It offers products online at the website (www.landsend.com), through third-party distribution channels, its own company-operated stores, and third-party license agreements. Lands' End also offers products to businesses and schools, for their employees and students, through the Outfitters distribution channel. The company's operating segments consist of: U.S. eCommerce, Europe eCommerce, Outfitters, Third Party, Licensing, and Retail. The majority of its revenue is generated from the U.S. eCommerce segment. Geographically, Lands' End derives maximum revenue from the United States, and the rest from Europe and other markets.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.